SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/C7270B2E299407B02B4E55E0987FD131C266D43E45549F54472EED1E7B276BC4A06123F1D9216577ED0EE74672C6FC03>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/C7270B2E299407B02B4E55E0987FD131C266D43E45549F54472EED1E7B276BC4A06123F1D9216577ED0EE74672C6FC03
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/C7270B2E299407B02B4E55E0987FD131C266D43E45549F54472EED1E7B276BC4A06123F1D9216577ED0EE74672C6FC03
http://www.w3.org/2000/01/rdf-schema#comment
"in the current study we evaluated the safety tolerability and pharmacokinetic (PK) characteristics of GC33 ( a humanized mAb against human glypican-3)in Japanese patients."
xsd:string
http://purl.uniprot.org/uniprot/#_4B6B61240CA4E4FAF29C6021C22C99C6296B89CF83DA2F11B15B3182423210571D21A4C7BB435A09DA8721EEF7FD6074
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/C7270B2E299407B02B4E55E0987FD131C266D43E45549F54472EED1E7B276BC4A06123F1D9216577ED0EE74672C6FC03
http://purl.uniprot.org/uniprot/I6QTG3
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/C7270B2E299407B02B4E55E0987FD131C266D43E45549F54472EED1E7B276BC4A06123F1D9216577ED0EE74672C6FC03
http://purl.uniprot.org/uniprot/#_I6QTG3-mappedCitation-24521523
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/C7270B2E299407B02B4E55E0987FD131C266D43E45549F54472EED1E7B276BC4A06123F1D9216577ED0EE74672C6FC03